⌘K

/

/

Accelerating fibrosis and inflammation research through validated preclinical models and expert insights.

Research

Models
Drugs
Insights

Company

CRO Partners
Contact Us
Privacy Policy

© 2025 Fibrosis-Inflammation Lab. All rights reserved.

Privacy Policy Terms of Service

Nerandomilast (nerandomilast) | Accelerate Your Fibrosis Research

Home/Drugs/Nerandomilast

Nerandomilast

nerandomilast

Approved

Sponsor: Kyorin Pharmaceutical

Indication: IPF

Mechanism of Action

Phosphodiesterase 4 (PDE4) inhibitor, reduces inflammation and fibrosis

Target: PDE4

Clinical Information

Approval Year

Clinical Trials (ClinicalTrials.gov)

COMPLETEDNCT06139302

A Study to Test How Different Doses of Nerandomilast (BI 1015550) Are Taken up in the Body of Healthy Japanese Men

Phase:PHASE1Org:Boehringer Ingelheim

NOT_YET_RECRUITING

Relevant Publications (PubMed)

No recent publications found for nerandomilast.

Validated Models

This drug has been validated in the following preclinical models:

NCT06241560

A Study in People With Idiopathic Pulmonary Fibrosis to Test Whether Pirfenidone Influences the Amount of BI 1015550 in the Blood

Phase:PHASE2Org:Boehringer Ingelheim

COMPLETEDNCT06070610

A Study in Healthy Men to Test Whether BI 1015550 Influences the Amount of Nintedanib and Pirfenidone in the Blood

Phase:PHASE1Org:Boehringer Ingelheim

COMPLETEDNCT05661344

A Study to Test How BI 1015550 is Taken up in the Blood of People With and Without Liver Problems

Phase:PHASE1Org:Boehringer Ingelheim

COMPLETEDNCT06415045

A Study in Healthy People to Test How BI 1015550 is Taken up in the Body When Given With or Without Food

Phase:PHASE1Org:Boehringer Ingelheim

View all trials on ClinicalTrials.gov